ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Fátima Cardoso, A. Costa, Larry Norton et al. · The Breast · 2014
SCOPUS: ar.j
Cited by 336 works. doi:10.1016/j.breast.2014.08.009 Open-access PDF
Authors
- Fátima Cardoso
- A. Costa
- Larry Norton
- Elżbieta Senkus
- Matti Aapro
- Fabrice André
- Carlos H. Barrios
- Jonas C. S. Bergh
- Laura Biganzoli
- Maria João Cardoso
- Tanja Čufer
- M. Ziad Saghir
- Lesley J. Fallowfield
- Doris Fenech
- Prudence A. Francis
- Karen A. Gelmon
- Sharon Hermes Giordano
- Joseph Gligorov
- Aron Goldhirsch
References
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
- Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
- Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
- Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial